Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Promethera to Launch Japan Trial of Cell Therapy Targeting ACLF by FY2021
December 24, 2019
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Bayer, Santen Extend Eylea Tie-Up in Japan
December 23, 2019
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
- Takecab Back on Top in Hospital Promotion Ranking in October: Impact Track
December 19, 2019
- Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
- Jardiance Delivers Favorable Data in Asian RWD Analysis: Boehringer/Lilly
December 19, 2019
- Daiichi Sankyo Aims to Become Global Leader of ADCs: CEO
December 18, 2019
- Chugai Names EVP Okuda as New President
December 18, 2019
- Xtandi Bags Label Expansion in US for Metastatic Castration-Sensitive Prostate Cancer: Astellas/Pfizer
December 18, 2019
- Meiji Pharma Begins PI for Stelara Biosimilar in Europe
December 17, 2019
- Astellas Launches Tender Offer for Audentes
December 17, 2019
- Rohto to Initiate Japan PI of JAK Inhibitor in Ophthalmology Field Later This Month
December 17, 2019
- Sumitomo Dainippon Pulls Plug on SanBio’s Lead Cell Therapy
December 16, 2019
- Asahi Kasei Launches Tender Offer for Veloxis
December 16, 2019
- UMN to Become Shionogi’s Subsidiary on Dec. 19
December 16, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…